Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ewing Sarcoma Breakpoint Region 1–Friend Leukemia Integration Factor 1 Fusion Protein (None)
- Target
- None
- Molecular classification
- Transcription factor, Fusion protein
01
Overview
EWS-FLI1 is an oncogenic fusion protein pathognomonic for Ewing sarcoma, resulting from a chromosomal translocation, most commonly t(11;22)(q24;q12), which fuses the N-terminal domain of the EWSR1 gene to the C-terminal DNA-binding domain of the FLI1 gene. It functions as an aberrant transcription factor, dysregulating genes involved in cell proliferation, differentiation, and survival. The fusion protein is localized to the nucleus and represents a therapeutic target for Ewing sarcoma.
- Other names
- EWS-FLI1EWS/FLI1EWS-FLI-1
02
Mechanism of action
Disruption of RHA interaction from EWS-FLI-1 and restoration of RHA helicase activity
03
Biological functions
Transcriptional regulationRNA processingCell proliferationOncogenesis
04
Disease associations
CancerEwing sarcoma
05
Safety considerations
Specificity of inhibitorsOff-target effectsResistance development
06
Interacting drugs
YK-4-279
07
Biomarkers
EWS-FLI1 fusion transcript type
Beyond the preview
Go deeper on Ewing Sarcoma Breakpoint Region 1–Friend Leukemia Integration Factor 1 Fusion Protein (None).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ewing Sarcoma Breakpoint Region 1–Friend Leukemia Integration Factor 1 Fusion Protein (None).